- Previous Close
25.70 - Open
25.70 - Bid 26.10 x --
- Ask 26.20 x --
- Day's Range
25.35 - 26.20 - 52 Week Range
24.00 - 39.85 - Volume
82,300 - Avg. Volume
243,143 - Market Cap (intraday)
3.461B - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-2.70 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.
www.brimbiotech.comRecent News: 6885.TW
View MorePerformance Overview: 6885.TW
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6885.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6885.TW
View MoreValuation Measures
Market Cap
3.46B
Enterprise Value
1.62B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.33k
Price/Book (mrq)
1.68
Enterprise Value/Revenue
4.86k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-10.29%
Return on Equity (ttm)
-16.64%
Revenue (ttm)
333k
Net Income Avi to Common (ttm)
-315.47M
Diluted EPS (ttm)
-2.70
Balance Sheet and Cash Flow
Total Cash (mrq)
1.85B
Total Debt/Equity (mrq)
0.38%
Levered Free Cash Flow (ttm)
50.82M